Atorvastatin (CI-981) clinical pharmacokinetic study (II) - Pharmacokinetics of single dose atorvastatin in healthy male volunteers -

Japanese Pharmacology and Therapeutics

Volumn 26, Issue 8, 1998, Pages 79-92

  Oishi, Shimako ^a   Watanabe, Takashi ^a   Higuchi, Saburo ^a   Matsumura, Masami ^a   Morita, Takeo ^a   Kikawa, Yoshio ^a   Tsunoo, Michio ^b   Obi, Shuntaro ^b   Momomura, Shin Ichi ^b   Kojo, Tooru ^b   Nakamura, Norihiko ^b  

^a Yamanouchi Pharmaceutical Co Ltd

^b Hosen Clinic

Author keywords

Atorvastatin; CI 981; Clinical pharmacokinetics; HMG CoA reductase inhibitor; Lipid regulator

Indexed keywords

ATORVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERANCE; HUMAN; HUMAN EXPERIMENT; HYPOLIPEMIA; MALE; NORMAL HUMAN;

EID: 7344248550     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Baumann KL et al : The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett 33 : 2283-2284, 1992
2. Nawrocki JW et al : Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15 : 678-682, 1995
3. Bakker-Arkema RG et al : Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275 : 128-133, 1996
4. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group: Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 79 : 1248-1252, 1997
5. Davidson MH et al : Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program Treatment Goals. Am J Cardiol 80 : 347-348, 1997
6. Naoumova RP et al : Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 119 : 203 213, 1996
7. CI-981 (Atorvastatin) 4 : 1559-1584, 1998
8. CI-981 (Atorvastatin) 40 mg 14 : 1585-1600, 1998
9. CI-981 (Atorvastatin) 14 : 1601-1611, 1998
10. CI-981 (Atorvastatin) 14 : 1613-1622, 1998
11. CI-981 (Atorvastatin) 40 mg 14 : 1623-1628, 1998
12. Shum YY et al : Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atrovastatin in plasma matrices. Ther Drug Monit 20 : 41-49, 1998
13. Chong PH, Seeger JD : Atorvastatin calcium : An addition to HMG-CoA reductase inhibitors. Pharmacotherapy 17 : 1157-1177, 1997
14. Michniewicz BM et al : In vitro and in vivo metabolism of atorvastatin (CI-981). Sixth North American ISSX Meeting, Abstract No. 93, Raleigh. NC, USA, 1994
15. Krause BR et al : In vitro and in vivo activities of atorvastatin metabolites. Warner-Lambert Company, Parke-Davis Pharmaceuticals No. RR741-00016, Ann Arbor, Michigan, USA, 1995